AU2019296117A1 - Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases - Google Patents

Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases Download PDF

Info

Publication number
AU2019296117A1
AU2019296117A1 AU2019296117A AU2019296117A AU2019296117A1 AU 2019296117 A1 AU2019296117 A1 AU 2019296117A1 AU 2019296117 A AU2019296117 A AU 2019296117A AU 2019296117 A AU2019296117 A AU 2019296117A AU 2019296117 A1 AU2019296117 A1 AU 2019296117A1
Authority
AU
Australia
Prior art keywords
compound
mmol
alkyl
hbv
purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019296117A
Other languages
English (en)
Inventor
Zhanling CHENG
Wing Shun CHEUNG
Gang Deng
Yimin Jiang
Chao Liang
Qian Liu
Zhao-Kui Wan
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of AU2019296117A1 publication Critical patent/AU2019296117A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019296117A 2018-06-26 2019-06-25 Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases Abandoned AU2019296117A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/092875 2018-06-26
CN2018092875 2018-06-26
US201862716823P 2018-08-09 2018-08-09
US62/716,823 2018-08-09
PCT/CN2019/092857 WO2020001448A1 (en) 2018-06-26 2019-06-25 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Publications (1)

Publication Number Publication Date
AU2019296117A1 true AU2019296117A1 (en) 2020-11-26

Family

ID=68984711

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019296117A Abandoned AU2019296117A1 (en) 2018-06-26 2019-06-25 Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases

Country Status (8)

Country Link
EP (1) EP3814326A4 (ko)
JP (1) JP2021529188A (ko)
KR (1) KR20210025596A (ko)
CN (1) CN112513017A (ko)
AU (1) AU2019296117A1 (ko)
CA (1) CA3099605A1 (ko)
MA (1) MA53023A (ko)
WO (1) WO2020001448A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11639350B2 (en) 2017-06-27 2023-05-02 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
US11053235B2 (en) * 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
CN114989097A (zh) * 2022-05-20 2022-09-02 无锡捷化医药科技有限公司 一种5-氨基-6-氯嘧啶-4-羧酸乙酯的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013305390C1 (en) * 2012-08-24 2015-12-24 Ruyuan Wei Xiang Technology Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
US10179131B2 (en) * 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11639350B2 (en) * 2017-06-27 2023-05-02 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections

Also Published As

Publication number Publication date
MA53023A (fr) 2021-05-05
CA3099605A1 (en) 2020-01-02
CN112513017A (zh) 2021-03-16
KR20210025596A (ko) 2021-03-09
EP3814326A4 (en) 2022-03-16
WO2020001448A1 (en) 2020-01-02
EP3814326A1 (en) 2021-05-05
JP2021529188A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
US10556904B2 (en) Derivatives and methods of treating hepatitis B infections
US10364228B2 (en) Azepane derivatives and methods of treating hepatitis B infections
AU2019296117A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases
AU2019266729A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases
US11053235B2 (en) Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
AU2020321067A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases
US20220348571A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
WO2022257942A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period